A new era in the treatment of erectile dysfunction: Chronic phosphodiesterase type 5 inhibition

BJU International

Volumn 105, Issue 12, 2010, Pages 1634-1639

  Fusco, Ferdinando ^a   Razzoli, Elisa ^b   Imbimbo, Ciro ^a   Rossi, Andrea ^b   Verze, Paolo ^a   Mirone, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ELI LILLY   (Italy)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Tadalafil

Indexed keywords

PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

BACKACHE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; EVENING DOSAGE; FLU LIKE SYNDROME; HEADACHE; HOMEOSTASIS; HUMAN; LOW DRUG DOSE; PATHOPHYSIOLOGY; PENIS ERECTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SHORT SURVEY; SINGLE DRUG DOSE;

CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 77952829688     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09244.x     Document Type: Short Survey

References (52)

1. Wespes E, Amar E, Hatzichristou D et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006 49 : 806 815
2. Hatzichristou D, Rosen RC, Broderick G et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004 1 : 4957
3. Hatzimouratidis K. Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance? J Men's Health Gender 2006 3 : 342 349
4. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006 332 : 589 592
5. Son H, Park K, Kim SW, Paick JS. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004 6 : 117 120
6. Jiann BP, Ou CW, Lin JT, Huang JK. Compression of ureter caused by a retained reservoir of penile prosthesis. Int J Impot Res 2006 18 : 316 317
7. Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005 7 : 57 65
8. Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S EDOS Group. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol 2007 51 : 541 550
9. McMahon CG. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004 1 : 292 300
10. Porst H, Giuliano F, Glina S et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006 50 : 351 359
11. McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol 2006 50 : 215 217
12. McMahon CG. Comparison, efficacy, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005 2 : 415 425
13. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002 25 : 1336 1339
14. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005 47 : 214 222
15. Halcox JP, Nour KR, Zalos G et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002 40 : 1232 1240
16. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000 36 : 845 851
17. Dishy V, Sofowora G, Harris PA et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001 70 : 270 279
18. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005 111 : 742 746
19. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007 19 : 200 207
20. Foresta C, Caretta N, Lana A et al. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol 2007 51 : 1411 1419
21. Foresta C, Ferlin A, De Toni L et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006 18 : 484 488
22. Hellstrom WJ, Kendirci M. Type 5 phosphodiesterase inhibitors: curing erectile dysfunction. Eur Urol 2006 49 : 942 945
23. Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006 61 : 280 288
24. Fugl-Meyer AR, Lodnert G, Bränholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997 9 : 141 148
25. Lewis R, Bennett CJ, Borkon WD et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 2001 57 : 960 965
26. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998 159 : 1541 1547
27. Eardley I, Mirone V, Montorsi F et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. BJU Int 2005 96 : 1323 1332
28. Sharlip ID, Shumaker BP, Hakim LS, Goldfischer E, Natanegara F, Wong DG. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States. J Sex Med 2008 5 : 716 725
29. Behr-Roussel D, Gorny D, Mevel K et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005 47 : 87 91
30. Caretta N, Palego P, Ferlin A et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration. The role of tadalafil. Eur Urol 2005 48 : 326 331
31. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol 2009 18 : 245 251
32. Vignozzi L, Filippi S, Morelli A et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 2006 3 : 419 431
33. Kovanecz I, Rambhatla A, Ferrini M et al. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 2008 20 : 202 212
34. Kovanecz I, Rambhatla A, Ferrini MG et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008 10 : 203 210
35. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006 68 : 429 435
36. Ferrini MG, Kovanecz I, Sanchez S et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007 76 : 915 923
37. De Young LX, Domes T, Lim K, Carson J, Brock GB. Endothelial rehabilitation. the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 2008, 54213 54220
38. Jung HG, Shin JH, Kim KW et al. Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor. Life Sci 2007 23 : 699 708
39. Mirone V, Costa P, Damber JE et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005 47 : 846 854 (Pubitemid 40745355)
40. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for 'non-responders' to tadalafil and vardenafil: a real-life study. Eur Urol 2006 50 : 126 133
41. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998 15 : 821 825
42. Hatzichristou D, Gambla M, Rubio-Aurioles E et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008 25 : 138 146
43. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007 9 : 134 141
44. Montorsi F, Brock G, Lee J et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008 54 : 924 931
45. El-Galley R, Rutland H, Talic R, Keane T, Clark H. Longterm efficacy of sildenafil and tachyphylaxis effect. J Urol 2001 166 : 927 931
46. Steers WD. Tachyphylaxis and phosphodiesterase type 5 inhibitors. J Urol 2002 168 : 207
47. Behr-Roussel D, Gorny D, Mevel K et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats. Lack of tachyphylaxis. Eur Urol 2005 47 : 87 91
48. Musicki B, Champion HC, Becker RE et al. In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect. J Urol 2005 174 : 1493 1496
49. Vernet D, Magee T, Qian A, Nolazco G, Rajfer J, Gonzalez-Cadavid N. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med 2006 3 : 84 94
50. Porst H, Rajfer J, Casabé A et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008 5 : 2160 9
51. Wrisko R, Sorsaburo S, Wong D, Strawbridge A, McGill J. Safety, efficacy and pharmacokinetic overview of low dose daily administration of tadalafil. Sex Med 2009 6 : 2039 2049
52. Hellstrom WJ, Gittelman M, Jarow J et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008 53 : 1058 1065